A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas

BACKGROUND: The MEK inhibitor, selumetinib, suppresses soft-tissue sarcoma (STS) cell proliferation in vitro. Mammalian target of rapamycin inhibitors possess modest activity against STS; however, resistance develops via MAPK pathway feedback activation. The combination of selumetinib and temsirolim...

Descripción completa

Detalles Bibliográficos
Autores principales: Eroglu, Z, Tawbi, H A, Hu, J, Guan, M, Frankel, P H, Ruel, N H, Wilczynski, S, Christensen, S, Gandara, D R, Chow, W A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430716/
https://www.ncbi.nlm.nih.gov/pubmed/25897676
http://dx.doi.org/10.1038/bjc.2015.126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430716/
https://www.ncbi.nlm.nih.gov/pubmed/25897676
http://dx.doi.org/10.1038/bjc.2015.126

Ejemplares similares